Ibrutinib, OBINUTUZUMAB, GDC-0199 clinical trials

A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs)

This study is testing new combinations of medicines for people in the UK with a type of blood cancer called Mantle Cell Lymphoma, which has come back or not responded to previous treatments. It aims to see how safe these new drug combinations are and how well they work.